P

Inventor

SCHAFER PETER H

US39 patents
⚠️ This page may combine multiple inventors who share the name “SCHAFER PETER H”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

CELGENE CORP

26 patents
US6962940B2Nov 8, 2005

(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof

CELGENE CORP107 citations99
US7893101B2Feb 22, 2011

Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof

CELGENE CORP44 citations98
US7427638B2Sep 23, 2008

(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof

CELGENE CORP53 citations97
US7659303B2Feb 9, 2010

Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-1,3-dione

CELGENE CORP21 citations96
US7659302B2Feb 9, 2010

Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione

CELGENE CORP35 citations96
US7507759B2Mar 24, 2009

Methods of using(+)-2-[1-(3-ethoxy-4methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3,-dione

CELGENE CORP21 citations96
US7358272B2Apr 15, 2008

Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione

CELGENE CORP21 citations96
US9724330B2Aug 8, 2017

Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione

CELGENE CORP7 citations93
US9283207B2Mar 15, 2016

Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione

CELGENE CORP7 citations93
US9018243B2Apr 28, 2015

Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof

CELGENE CORP13 citations93
US8802717B2Aug 12, 2014

Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione

CELGENE CORP13 citations93
US10047151B2Aug 14, 2018

Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor

CELGENE CORP19 citations92
US7276529B2Oct 2, 2007

Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione

CELGENE CORP28 citations90
US7208516B2Apr 24, 2007

Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione

CELGENE CORP40 citations90
US10092542B2Oct 9, 2018

Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione

CELGENE CORP4 citations84
US9857359B2Jan 2, 2018

Methods for determining drug efficacy using cereblon-associated proteins

CELGENE CORP11 citations81
US10751414B2Aug 25, 2020

Methods of treating psoriasis using PD-1 binding antibodies

CELGENE CORP9 citations78
US11660302B2May 30, 2023

3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

CELGENE CORP1 citations73
US10980812B2Apr 20, 2021

3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

CELGENE CORP2 citations73
US10596179B2Mar 24, 2020

3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

CELGENE CORP1 citations73
US10245266B2Apr 2, 2019

3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

CELGENE CORP3 citations73
US9433606B2Sep 6, 2016

Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof

CELGENE CORP3 citations73
US10919883B2Feb 16, 2021

Treatment of immune-related and inflammatory diseases

CELGENE CORP0 citations62
US12064437B2Aug 20, 2024

Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies

CELGENE CORP0 citations59
US11524950B2Dec 13, 2022

Treatment of immune-related and inflammatory diseases

CELGENE CORP0 citations58
US9480676B2Nov 1, 2016

Use of PDE4 inhibitors and combinations thereof for the treatment of cystic fibrosis

CELGENE CORP0 citations42

MULLER GEORGE W

4 patents

AMGEN INC

3 patents

SCHAFER PETER H

3 patents

LOPEZ-GIRONA ANTONIA

1 patent

BARTLETT JUSTIN B

1 patent

CELGENE INT II SARL

1 patent